改良FOLFOX方案治疗中晚期原发性肝癌临床观察  

Clinical study on mFOLFOX6 regimen as systemic chemotherapy for advanced hepatocellular carcinoma

作　　者：王文舟[1] WANG Wen-zhou(The Second People＇s Hospital of Chizhou 247000,Anhu)

机构地区：[1]池州市第二人民医院肿瘤科,安徽池州247000

出　　处：《安徽卫生职业技术学院学报》2018年第4期43-44,共2页Journal of Anhui Health Vocational & Technical College

摘　　要：目的:观察m FOLFOX6方案治疗晚期原发性肝癌(HCC)的疗效和安全性。方法:31例晚期HCC患者接受m FOLFOX6方案化疗,观察疾病进展时间(TTP)和总生存期(OS)。结果:全组患者中31例可评价疗效,获PR 8例,SD 13例,PD 10例,客观缓解率(RR)为25.8%,疾病控制率(DCR)为67.7%,中位TTP为3.5月,中位OS为7.2月。结论:m FOLFOX6方案用于中晚期HCC化疗,患者取得较好的疾病控制与生存延长,不良反应较轻,值得临床进一步推广。Objective：To observe the efficacy and safety of oxaliplatin（ OXA） combined with CF/5-FU as m FOLFOX6 regimen for patients with hepatocellular carcinoma（ HCC）.Methods：31 patients were treated with m FOLFOX6 regimen as systemic chemotherapy.The time to progression（ TTP） and overall survival（ OS） were observed.Results：Thrity-one patients were observed and evaluatable for efficacy.eight patients obtained partial response（ PR）,thirteen patients stable disease（ SD） and ten patients disease progression（ PD）.The objective response rate（ RR） was 25.8% and disease control rate（ DCR） was 67.7%. The median TTP and median OS were 3.5 months and 7.2 months,respectively.Conclusion：Systemic chemotherapy with OXA-based m FOLFOX6 regimen for advanced HCC shows better disease control and survival benefit with mild adverse effects.Thus,it＇s worthy of further clinical application widely.

关 键 词：原发性肝癌 奥沙利铂 mFOLFOX6方案 化疗 

分 类 号：R735.7[医药卫生—肿瘤]